Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as its initiating director of operations have announced the closure of its seed investment round. This pre-seed investment will be used to advance Phlox’s lead program focused on rare genetic laminopathies. Funding was provided by FIRST fund, managed by BioGeneration Ventures (BGV).
Existing therapies conspicuously fail to halt the progression of hereditary forms of heart failure. Ironically, this most often concerns young patients, leaving them with a therapy resistant form of heart failure. This includes patients with heart failure caused by mutations in the lamin A/C gene, also known as laminopathies, a distinct and often aggressive form of heart failure. Phlox’s technology uses smart RNA-designs that allow for parallel targeting of multiple Lamin A/C mutations. The versatile nature of these RNA-designs, developed by the Amsterdam UMC team, prevents the need for generating mutation specific compounds to treat each unique mutation, making these compounds efficacious for the majority of patients harboring a Lamin A/C mutation. Proof-of-concept experiments show that these compounds can induce highly selective and favorable therapeutic effects in human stem cell-derived cardiomyocytes from patients suffering from laminopathy. Next to mutations in Lamin A/C, Phlox Therapeutics aims to apply its smart designs to adjacent treatment resistant cardiomyopathies.
Yigal Pinto, cardiologist and CMO of Phlox Therapeutics: “My aspiration for initiating Phlox was triggered when I started to treat a large family with an aggressive mutation in the Lamin A/C gene, causing a severe type of heart failure that did not respond to our commonly used therapies. This harsh reality drove my team and I to seek new opportunities to relieve the burden of this gene mutation. Current developments in RNA therapeutics have greatly accelerated our efforts to develop our proprietary technology to target the root cause of the problem in patients with mutations in the Lamin A/C gene. Therefore, I am very excited to collaborate with the dedicated Phlox Therapeutics team and partners to further progress this technology making it available for our patients that are suffering from this destructive disease.”
Anya Biotech, representing Amsterdam UMC, has won the second edition of the Proefdiervrij Venture Challenge on the 22nd of April 2022. Their winning innovation is based on research from the Department of Medical Biology at the AMC. The team takes home €25.000, – in prize money to kick-start their venture based on human heart models […]News
Sem Vijverberg – PhD Candidate at Vrije Universiteit Amsterdam – and University of Amsterdam PostDoc researcher Tijmen Bakker have been selected as participants in the Faculty of Impact, and will be taking part in an intensive two year program where ten ambitious scientists work with each other and with a selection of experts to conquer […]News
Every language contains riddles and secrets, currently there are seven thousand+ known languages. A treasure trove of colourful, curious and enigmatic stories. Every language tells a story about and gives a picture of the culture and the people that speak or have spoken this language. And every language is full of riddles and secrets that […]News